Refametinib (BAY86-9766)

DRUG4 trials

Sponsors

Bayer

Conditions

Carcinoma, HepatocellularNeoplasms

Phase 1

BAY86-9766 Plus Gemcitabine Phase I Study in Asian

CompletedNCT01764828

Start: 2013-02-05End: 2015-02-10Updated: 2018-11-01

Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer

TerminatedNCT02168777

Start: 2014-06-23End: 2016-04-05Updated: 2018-01-26

Phase 2

Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)

CompletedNCT01915589

BayerCarcinoma, Hepatocellular

Start: 2013-09-16End: 2014-10-08Updated: 2021-04-08

Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)

CompletedNCT01915602

BayerCarcinoma, Hepatocellular

Start: 2013-09-27End: 2017-02-08Updated: 2021-04-08

Related Papers

Abstract 5252: Liquid biopsies to prospectively select patients with <i>KRAS</i> or <i>NRAS</i> mutant hepatocellular carcinoma (HCC) in two phase II studies with Refametinib

Cancer Research2015-08-011 citations

Abstract B42: RAS mutations detected by cell-free plasma DNA (BEAMing) assay may portend a favorable response to refametinib +/- sorafenib in hepatocellular carcinoma

Molecular Cancer Research2014-12-01